<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28324125</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>09</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-0851</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>66</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cancer immunology, immunotherapy : CII</Title>
          <ISOAbbreviation>Cancer Immunol Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Exercise and cancer: from "healthy" to "therapeutic"?</ArticleTitle>
        <Pagination>
          <StartPage>667</StartPage>
          <EndPage>671</EndPage>
          <MedlinePgn>667-671</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00262-017-1985-z</ELocationID>
        <Abstract>
          <AbstractText>Exercise improves functional capacity and patient-reported outcomes across a range of cancer diagnoses. The mechanisms behind this protection have been largely unknown, but exercise-mediated changes in body composition, sex hormone levels, systemic inflammation, and immune cell function have been suggested to play a role. We recently demonstrated that voluntary exercise leads to an influx of immune cells in tumors, and a more than 60% reduction in tumor incidence and growth across several mouse models. Given the common mechanisms of immune cell mobilization in mouse and man during exercise, we hypothesize that this link between exercise and the immune system can be exploited in cancer therapy in particular in combination with immunotherapy. Thus, we believe that exercise may not just be "healthy" but may in fact be therapeutic.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Idorn</LastName>
            <ForeName>Manja</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Center for Cancer Immune Therapy (CCIT), University Hospital Herlev, Herlev Ringvej 75, 2730, Herlev, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thor Straten</LastName>
            <ForeName>Per</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0002-4731-4969</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Center for Cancer Immune Therapy (CCIT), University Hospital Herlev, Herlev Ringvej 75, 2730, Herlev, Denmark. per.thor.straten@regionh.dk.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. per.thor.straten@regionh.dk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>03</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cancer Immunol Immunother</MedlineTA>
        <NlmUniqueID>8605732</NlmUniqueID>
        <ISSNLinking>0340-7004</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005081" MajorTopicYN="N">Exercise Therapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CIMT 2016</Keyword>
        <Keyword MajorTopicYN="N">Combination treatment</Keyword>
        <Keyword MajorTopicYN="N">Exercise</Keyword>
        <Keyword MajorTopicYN="N">Immune cell mobilization</Keyword>
        <Keyword MajorTopicYN="N">NK cells</Keyword>
        <Keyword MajorTopicYN="N">Tumor infiltration</Keyword>
      </KeywordList>
      <CoiStatement>The authors have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>7</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>3</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28324125</ArticleId>
        <ArticleId IdType="pmc">PMC5406418</ArticleId>
        <ArticleId IdType="doi">10.1007/s00262-017-1985-z</ArticleId>
        <ArticleId IdType="pii">10.1007/s00262-017-1985-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kujala UM, Kaprio J, Sarna S, Koskenvuo M. Relationship of leisure-time physical activity and mortality: the Finnish twin cohort. JAMA. 1998;279:440–444. doi: 10.1001/jama.279.6.440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.279.6.440</ArticleId>
            <ArticleId IdType="pubmed">9466636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore SC, Lee IM, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, Keadle SK, Arem H, de Berrington GA, Hartge P, Adami HO, Blair CK, Borch KB, Boyd E, Check DP, Fournier A, Freedman ND, Gunter M, Johannson M, Khaw KT, Linet MS, Orsini N, Park Y, Riboli E, Robien K, Schairer C, Sesso H, Spriggs M, Van DR, Wolk A, Matthews CE, Patel AV. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44million adults. JAMA Intern Med. 2016;176:816–825. doi: 10.1001/jamainternmed.2016.1548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamainternmed.2016.1548</ArticleId>
            <ArticleId IdType="pmc">PMC5812009</ArticleId>
            <ArticleId IdType="pubmed">27183032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McTiernan A. Mechanisms linking physical activity with cancer. Nat Rev Cancer. 2008;8:205–211. doi: 10.1038/nrc2325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2325</ArticleId>
            <ArticleId IdType="pubmed">18235448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104:815–840. doi: 10.1093/jnci/djs207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djs207</ArticleId>
            <ArticleId IdType="pmc">PMC3465697</ArticleId>
            <ArticleId IdType="pubmed">22570317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pedersen L, Idorn M, Olofsson GH, Nookaew I, Hvass Hansen R, Hjort Johannesen H, Becker JC, Lauenborg B, Pedersen KS, Dethlevsen C, Nielsen J, Gehl J, Pedersen BK, thor Straten P, Hojman P. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metab. 2016;23:554–562. doi: 10.1016/j.cmet.2016.01.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2016.01.011</ArticleId>
            <ArticleId IdType="pubmed">26895752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319:675–678. doi: 10.1038/319675a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/319675a0</ArticleId>
            <ArticleId IdType="pubmed">3951539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walsh NP, Gleeson M, Shephard RJ, Gleeson M, Woods JA, Bishop NC, Fleshner M, Green C, Pedersen BK, Hoffman-Goetz L, Rogers CJ, Northoff H, Abbasi A, Simon P. Position statement. Part one: immune function and exercise. Exerc Immunol Rev. 2011;17:6–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21446352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gleeson M, Bishop NC. The T cell and NK cell immune response to exercise. Ann Transplant. 2005;10:43–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17037088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Timmons BW, Cieslak T. Human natural killer cell subsets and acute exercise: a brief review. Exerc Immunol Rev. 2008;14:8–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19203081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shephard RJ, Shek PN. Effects of exercise and training on natural killer cell counts and cytolytic activity: a meta-analysis. Sports Med. 1999;28:177–195. doi: 10.2165/00007256-199928030-00003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00007256-199928030-00003</ArticleId>
            <ArticleId IdType="pubmed">10541441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dimitrov S, Lange T, Born J. Selective mobilization of cytotoxic leukocytes by epinephrine. J Immunol. 2010;184:503–511. doi: 10.4049/jimmunol.0902189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.0902189</ArticleId>
            <ArticleId IdType="pubmed">19949113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schedlowski M, Hosch W, Oberbeck R, Benschop RJ, Jacobs R, Raab HR, Schmidt RE. Catecholamines modulate human NK cell circulation and function via spleen-independent beta 2-adrenergic mechanisms. J Immunol. 1996;156:93–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8598500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cullen T, Thomas AW, Webb R, Hughes MG. Interleukin-6 and associated cytokine responses to an acute bout of high-intensity interval exercise: the effect of exercise intensity and volume. Appl Physiol Nutr Metab. 2016;41:803–808. doi: 10.1139/apnm-2015-0640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1139/apnm-2015-0640</ArticleId>
            <ArticleId IdType="pubmed">27377137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Pedersen BK. IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab. 2002;283:E1272–E1278. doi: 10.1152/ajpendo.00255.2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpendo.00255.2002</ArticleId>
            <ArticleId IdType="pubmed">12388119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bigley AB, Rezvani K, Chew C, Sekine T, Pistillo M, Crucian B, Bollard CM, Simpson RJ. Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Brain Behav Immun. 2014;39:160–171. doi: 10.1016/j.bbi.2013.10.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbi.2013.10.030</ArticleId>
            <ArticleId IdType="pubmed">24200514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol. 2016;16:112–123. doi: 10.1038/nri.2015.9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2015.9</ArticleId>
            <ArticleId IdType="pubmed">26806484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lanier LL. NKG2D receptor and its ligands in host defense. Cancer Immunol Res. 2015;3:575–582. doi: 10.1158/2326-6066.CIR-15-0098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-15-0098</ArticleId>
            <ArticleId IdType="pmc">PMC4457299</ArticleId>
            <ArticleId IdType="pubmed">26041808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fridman WH, Remark R, Goc J, Giraldo NA, Becht E, Hammond SA, Damotte D, Dieu-Nosjean MC, Sautes-Fridman C. The immune microenvironment: a major player in human cancers. Int Arch Allergy Immunol. 2014;164:13–26. doi: 10.1159/000362332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000362332</ArticleId>
            <ArticleId IdType="pubmed">24852691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guillerey C, Smyth MJ. NK cells and cancer immunoediting. Curr Top Microbiol Immunol. 2015;341:37–58.</Citation>
        </Reference>
        <Reference>
          <Citation>Stojanovic A, Correia MP, Cerwenka A. Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron. 2013;6:135–146. doi: 10.1007/s12307-012-0125-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12307-012-0125-8</ArticleId>
            <ArticleId IdType="pmc">PMC3717064</ArticleId>
            <ArticleId IdType="pubmed">23242671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356:1795–1799. doi: 10.1016/S0140-6736(00)03231-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(00)03231-1</ArticleId>
            <ArticleId IdType="pubmed">11117911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol. 2015;33:23–35. doi: 10.1016/j.coi.2015.01.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coi.2015.01.006</ArticleId>
            <ArticleId IdType="pubmed">25621841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer. 2014;2:14. doi: 10.1186/2051-1426-2-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/2051-1426-2-3</ArticleId>
            <ArticleId IdType="pmc">PMC4019906</ArticleId>
            <ArticleId IdType="pubmed">24829760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersen R, Donia M, Ellebaek E, Holz Borch T, Kongsted P, Iversen TZ, Rosenkrantz Hölmich L, Westergren Hendel H, Met O, Andersen MH, thor Straten P, Svane IM. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL-2 regimen. Clin Cancer Res. 2016;22:3734–3745. doi: 10.1158/1078-0432.CCR-15-1879.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-1879</ArticleId>
            <ArticleId IdType="pubmed">27006492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550–4557. doi: 10.1158/1078-0432.CCR-11-0116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-0116</ArticleId>
            <ArticleId IdType="pmc">PMC3131487</ArticleId>
            <ArticleId IdType="pubmed">21498393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, Van EP, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54–61. doi: 10.1038/nm1523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1523</ArticleId>
            <ArticleId IdType="pubmed">17187072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remedios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tuting T, Belardelli F, Bracci L, La S, V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Preville X, Uze G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, Andre F, Kroemer G, Zitvogel L. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20:1301–1309. doi: 10.1038/nm.3708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3708</ArticleId>
            <ArticleId IdType="pubmed">25344738</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
